Vanguard Group Inc Acurx Pharmaceuticals, Inc. Transaction History
Vanguard Group Inc
- $5.46 Trillion
- Q3 2024
A detailed history of Vanguard Group Inc transactions in Acurx Pharmaceuticals, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 529,349 shares of ACXP stock, worth $449,946. This represents 0.0% of its overall portfolio holdings.
Number of Shares
529,349
Previous 491,687
7.66%
Holding current value
$449,946
Previous $1.11 Million
9.13%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding ACXP
# of Institutions
26Shares Held
1.25MCall Options Held
9.3KPut Options Held
9.7K-
Prospect Financial Services LLC Melville, NY295KShares$250,8130.35% of portfolio
-
Geode Capital Management, LLC Boston, MA147KShares$124,5250.0% of portfolio
-
Morgan Stanley New York, NY46.2KShares$39,2700.0% of portfolio
-
Lpl Financial LLC Fort Mill, SC44.8KShares$38,0630.0% of portfolio
-
State Street Corp Boston, MA43.5KShares$36,9460.0% of portfolio
About Acurx Pharmaceuticals, Inc.
- Ticker ACXP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,556,600
- Market Cap $9.82M
- Description
- Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The com...